Ready for Prime Time? Dendritic Cells in High-Grade Gliomas.
Ready for Prime Time? Dendritic Cells in High-Grade Gliomas.
复制标题
作者：
尽管免疫系统可以对中枢神经系统内的抗原产生有效的反应，但这并不发生在高级别胶质瘤的情况下。树突状细胞（DC）被认为是初级抗原呈递者，通过肿瘤抗原和T细胞呈递以及T细胞迁移的趋化因子的分泌，对启动抗肿瘤免疫反应至关重要。许多免疫疗法依赖于树突状细胞的抗原呈递，然而树突状细胞在脑肿瘤（如高级别胶质瘤）的特定背景下的研究尚不充分。因此，本文总结了树突状细胞在高级别胶质瘤肿瘤微环境中的存在和功能，并特别考虑了治疗机会。高级别胶质瘤是恶性脑肿瘤，尽管出现了旨在促进免疫系统消除肿瘤的免疫疗法，但患者的预后仍然令人沮丧。一种强大的抗肿瘤免疫反应需要树突状细胞（DC）将肿瘤抗原呈递到原细胞溶解T细胞。然而，在高级别胶质瘤的背景下，树突状细胞活性的研究缺乏。因此，本综述涵盖了DC在中枢神经系统中的作用、DC浸润高级别胶质瘤、肿瘤抗原引流、DC活性的免疫原性以及参与抗肿瘤免疫反应的DC亚群。最后，我们考虑了免疫疗法背景下DC功能次优的影响，并确定了优化免疫疗法治疗高级别胶质瘤的机会。
Although the immune system can mount effective responses against antigens within the CNS, this does not occur in the context of high-grade gliomas. Considered to be the primary antigen presenters, dendritic cells (DC) are essential for initiating antitumor immune responses through tumor antigen and presentation to T cells and through the secretion of chemokines for T cell migration. Many immunotherapies depend on antigen presentation by dendritic cells, yet dendritic cells are understudied in the specific context of brain tumors such as high-grade gliomas. Accordingly, this review summarizes the presence and function of dendritic cells within the tumor microenvironment of high-grade gliomas with special consideration of therapeutic opportunities. High-grade gliomas are malignant brain tumors, and patient outcomes remain dismal despite the emergence of immunotherapies aimed at promoting tumor elimination by the immune system. A robust antitumor immune response requires the presentation of tumor antigens by dendritic cells (DC) to prime cytolytic T cells. However, there is a paucity of research on dendritic cell activity in the context of high-grade gliomas. As such, this review covers what is known about the role of DC in the CNS, DC infiltration of high-grade gliomas, tumor antigen drainage, the immunogenicity of DC activity, and DC subsets involved in the antitumor immune response. Finally, we consider the implications of suboptimal DC function in the context of immunotherapies and identify opportunities to optimize immunotherapies to treat high-grade gliomas.
登录
查看更多内容
影响因子：
5.2
作者：
Cao, Toni Q.;Wainwright, Derek A.;Lee-Chang, Catalina;Miska, Jason;Sonabend, Adam M.;Heimberger, Amy B.;Lukas, Rimas, V
通讯作者：
Lukas, Rimas, V
影响因子：
6.4
作者：
Authier, Astrid;Farrand, Kathryn J.;Hermans, Ian F.
通讯作者：
Hermans, Ian F.
DOI：
10.1084/jem.192.12.1685
发表时间：
2000-12-18
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
den Haan JM;Lehar SM;Bevan MJ
通讯作者：
Bevan MJ
DOI：
10.1001/jama.1928.02690380007003
发表时间：
1928-01-01
影响因子：
--
作者：
Dandy, WE
通讯作者：
Dandy, WE
影响因子：
64.5
作者：
Binnewies, Mikhail;Mujal, Adriana M.;Krummel, Matthew F.
通讯作者：
Krummel, Matthew F.